Helixmith Co., Ltd
084990 | KO
Overview
Corporate Details
- ISIN(s):
- KR7084990001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로7길 21, 강서구
- Website:
- https://www.helixmith.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-18 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.3 MB | ||
| 2025-07-09 00:00 |
AGM Information
임시주주총회결과
|
Korean | 6.1 KB | ||
| 2025-06-19 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 51.3 KB | ||
| 2025-06-18 00:00 |
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
|
Korean | 15.2 KB | ||
| 2025-06-18 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 48.4 KB | ||
| 2025-05-16 00:00 |
Quarterly Report
[기재정정]분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.0 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 5.7 KB | ||
| 2025-05-02 00:00 |
Legal Proceedings Report
소송등의판결ㆍ결정 (주주총회소집허가)
|
Korean | 6.2 KB | ||
| 2025-03-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.0 KB | ||
| 2025-03-27 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-03-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 10.1 KB |
Automate Your Workflow. Get a real-time feed of all Helixmith Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Helixmith Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Helixmith Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
United States of America
MGNX
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
United States of America
MDGL
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Sweden
MAGLE
Developing telomere-targeting immuno-oncology therapies for difficult-to-treat cancers.
United States of America
MAIA
United States of America
MAIA
Germany
MYNZ
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
United States of America
MNKD
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
United States of America
MRVI
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Austria
MARI
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
United States of America
MRKR
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE
United States of America
MAZE